Potential Metabolite Biomarkers for Early Detection of Stage-I Pancreatic Ductal Adenocarcinoma

Abstract

Background & ObjectivesPancreatic ductal adenocarcinoma remains an extremely malignant tumor having a poor prognosis. The 5-year survival rate of PDAC is related to its stage (about 80% for stage I vs 20% for other stages). However, detection of PDAC in an early stage is difficult due to the lack of effective screening methods. In this study, we aimed to construct a novel metabolic model for stage-I PDAC detection, using both serum and tissue samples.MethodsWe employed an untargeted technique, UHPLC-Q-TOF-MS, to identify the potential metabolite, and then used a targeted technique, GC-TOF-MS, to quantitatively validate. Multivariate and univariate statistics were performed to analyze the metabolomic profiles between stage-I PDAC and healthy controls, including 90 serum and 53 tissue samples. 28 patients with stage-I PDAC and 62 healthy controls were included in this study.ResultsA total of 10 potential metabolites presented the same expression levels both in serum and in tissue. Among them, a 2-metabolites-model (isoleucine and adrenic acid) for stage-I PDAC was constructed. The area under the curve (AUC) value was 0.93 in the discovery set and 0.90 in the independent validation set. Especially, the serum metabolite model had a better diagnostic performance than CA19-9 (AUC = 0.79). Pathway analysis revealed 11 altered pathways in both serum and tissue of stage-I PDAC.ConclusionsThis study developed a novel serum metabolites model that could early separate stage-I PDAC from healthy controls.

Metabolomic biomarkers in liquid biopsy: accurate cancer diagnosis and prognosis monitoring

“…Based on serum metabolomics, two studies observed reduced leucine levels in renal tumors and small cell lung cancer (SCLC), respectively ( 16 , 29 ). Consistent with these findings, patients with pancreatic ductal adenocarcinoma also had reduced levels of two isomers of leucine: isoleucine and ortholeucine ( 39 ). Decreased levels of BCAAs have also been detected in saliva samples from patients with cancer, including oral squamous cell carcinoma, lung cancer and thyroid cancer ( 38 , 41 , 42 ), implying vigorous catabolism of BCAAs in cancer cells to meet the energy requirements of biological macromolecules.…”

Assessment of Untargeted Metabolomics by Hydrophilic Interaction Liquid Chromatography−Mass Spectrometry to Define Breast Cancer Liquid Biopsy-Based Biomarkers in Plasma Samples

“…Lately, the utilization of mass spectrometry-based techniques to detect metabolic profiles in blood has emerged as a selective and sensitive tool to improve diagnosis of malignant diseases, including several types of cancers (such as colorectal, gastroenterological or pancreatic cancers) [25][26][27][28]. Specifically, metabolomic analyses of BC have widely demonstrated that metabolic dysregulation in cancer might be detected in a simple and cost-effective manner which may yield potential biomarkers of the disease behavior after further validation.…”

Mitochondrial Sirtuins in Chronic Degenerative Diseases: New Metabolic Targets in Colorectal Cancer

“…Pancreatic cancer, the deadliest and malignant cancers as a consequence of the difficulty to identify it in early stages [ 71 ], is also influenced by SIRTs activity and expression. SIRT5 expression is directly correlated to positive prognosis, as its loss promotes glutamic-oxaloacetic transaminase 1 (GOT1) acetylation, thus promoting cell proliferation by enhancing glutamine and glutathione metabolism [ 72 ].…”